Gilead
I received my PhD in pharmaceutical sciences from Temple university, Philadelphia. My doctoral thesis was focused on preclinical pharmacokinetics and its application in understanding chemotherapy related cognitive deficits Upon completion of my doctoral degree, I joined the PPDM group at Merck, Palo Alto. While at Merck, I worked on multiple projects with a wide variety of antibodies, and antibody derived modalities, especially within the immune oncology and cardiovascular space. Following Merck, I joined Harpoon Therapeutics, where I led all clinical pharmacology related activities for multiple CD3- bispecifics for both solid and heme tumors. Currently I represent the clinical pharmacology group (immune oncology) within Gilead Sciences for both antibody and small molecule programs.
Disclosure information not submitted.
Thursday, March 17, 2022
10:12 AM – 10:15 AM ET
.png)